Oncology Consultants PA
Houston, TX
Filters
Save & Share
Clear Filters
Accepting patients
TY-2136b
A Phase I, Multicenter, Open-label Study of TY-2136b, Administered Orally in Patients With Advanced or Metastatic Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations
Learn more- Tyrosine Kinase (TK) Inhibitor
- Phase 1
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials